Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
Tagliamento M, Morfouace M, Loizides C, Oliveira J, Greillier L, Raimbourg J, Toffart AC, Chatellier T, Cloarec N, Sullivan I, Brasiuniene B, Duruisseaux M, Oselin K, Robert MS, Fernandes C, Poncin A, Blay JY, Besse B, Girard N. Tagliamento M, et al. Among authors: sullivan i. NPJ Precis Oncol. 2024 Feb 16;8(1):37. doi: 10.1038/s41698-024-00518-9. NPJ Precis Oncol. 2024. PMID: 38366021 Free PMC article.
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
Cortellini A, Ricciuti B, Facchinetti F, Alessi JVM, Venkatraman D, Dall'Olio FG, Cravero P, Vaz VR, Ottaviani D, Majem M, Piedra A, Sullivan I, Lee KA, Lamberti G, Hussain N, Clark J, Bolina A, Barba A, Benitez JC, Gorría T, Mezquita L, Hoton D, Aboubakar Nana F, Besse B, Awad MM, Pinato DJ. Cortellini A, et al. Among authors: sullivan i. Ann Oncol. 2021 Nov;32(11):1391-1399. doi: 10.1016/j.annonc.2021.08.1744. Epub 2021 Aug 13. Ann Oncol. 2021. PMID: 34400292 Free article.
Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents.
Riudavets M, Mosquera J, Garcia-Campelo R, Serra J, Anguera G, Gallardo P, Sullivan I, Barba A, Del Carpio L, Barnadas A, Gich I, Majem M. Riudavets M, et al. Among authors: sullivan i. Front Oncol. 2020 Sep 7;10:1677. doi: 10.3389/fonc.2020.01677. eCollection 2020. Front Oncol. 2020. PMID: 33014837 Free PMC article.
Epidermolysis bullosa acquisita induced by atezolizumab.
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: sullivan i. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203. Epub 2023 Sep 1. J Dtsch Dermatol Ges. 2023. PMID: 37658659 No abstract available.
[Epidermolysis bullosa acquisita ausgelöst durch Atezolizumab].
Carmona-Rocha E, Aguado M, Tubau C, Sánchez S, Mozos A, Sullivan I, Spertino J. Carmona-Rocha E, et al. Among authors: sullivan i. J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203_g. J Dtsch Dermatol Ges. 2023. PMID: 37946658 German. No abstract available.
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study.
Piedra A, Martínez-Recio S, Hernández A, Morán T, Arriola E, Recuero-Borau J, Cobo M, Cordeiro P, Mosquera J, Fernández M, García-Campelo R, Calles A, Álvarez R, Zapata-García M, Isla D, Callejo A, Iranzo P, Serra-López J, Barba A, Sullivan I, Felip E, Majem M. Piedra A, et al. Among authors: sullivan i. Front Oncol. 2024 Dec 17;14:1510278. doi: 10.3389/fonc.2024.1510278. eCollection 2024. Front Oncol. 2024. PMID: 39741981 Free PMC article.
193 results